IMMUNICUM
Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology.
IMMUNICUM
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2002-01-01
Address:
Gothenburg, Vastra Gotaland, Sweden
Country:
Sweden
Website Url:
http://www.immunicum.se
Total Employee:
11+
Status:
Active
Contact:
(463)141-5052
Email Addresses:
[email protected]
Total Funding:
54.6 M USD
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Japanese Yen Google Maps For Work Barracuda Networks IP-Only Sweden
Similar Organizations
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.immunicum.se
- Host name: redirect1-1.ilait.se
- IP address: 62.109.34.30
- Location: Sölvesborg Sweden
- Latitude: 56.0521
- Longitude: 14.5753
- Timezone: Europe/Stockholm
- Postal: 294 32
More informations about "Immunicum"
Immunicum - Crunchbase Company Profile & Funding
Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of …See details»
Immunicum addresses essential challenges in cancer therapy
Immunicum changes name to Mendus - BioStock
Jul 1, 2022 The Swedish Companies Registration Office has approved Immunicum’s name change, and the company is now known as Mendus. Since June 27, the company has been …See details»
Immunicum AB: Immunicum Announces Corporate Rebranding …
Jun 23, 2022 Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell …See details»
Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST) - Life …
Rohmann, Sven (Immunicum 202011 CEO before Biotech Pharmacon 200810– VP BusDev before Novartis Pharma) Person 2 Zeilemaker, Sijme (Immunicum 201703– Director Business …See details»
Immunicum announces updated executive management team
Mar 16, 2021 Immunicum has announced the establishment of an updated executive management team following the initial integration period of the business combination with …See details»
Immunicum can look back on a transformative 2021
Jan 11, 2022 BioStock reached out to Immunicum’s CEO Erik Manting to get his thoughts on the company’s achievements during 2021 and what to expect from Immunicum in 2022. At the end of 2020, Stockholm-based Immunicum …See details»
Immunicum Company Profile - Office Locations, Competitors, …
Jul 19, 2024 Immunicum is a biopharmaceutical company that develops immune therapies against a range of various tumors. The Company's lead product, ilixadencel, has been …See details»
Immunicum AB (IMMU) Information - RocketReach
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and …See details»
20210412 Immunicum Annual Report Publication FINAL ENG
Immunicum AB (publ)| Östermalmstorg 5, 114 42 Stockholm| Tel +46 87328 400| Orgnr. 556629-1786|immunicum.se Press Release 12 April 2021 Immunicum AB (publ) Publishes the Annual …See details»
Immunicum AB Company Profile: , Investments, Contact …
Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary …See details»
Immunicum Publishes Year-End Letter by CEO and Announces …
Dec 21, 2021 The CEO year-end letter is published on the Immunicum website.Immunicum’s “Pipeline and Strategy Outlook” event will take place from 6:00 – 7:00 p.m. CET on February …See details»
BioStock Studio: Immunicum’s CEO on the company’s new …
Sep 13, 2021 Swedish immunotherapy company Immunicum has broadened its cancer treatment focus with the addition of drug candidate DCP-001 thanks to the merger with Dutch …See details»
Immunicum AB: Immunicum AB (publ) Publishes the Annual …
Apr 15, 2022 ABOUT IMMUNICUM AB (PUBL) Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two …See details»
Immunicum AB: Invitation to Immunicum's Full-Year 2021 Review …
Feb 10, 2022 Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on the prevention of cancer recurrence and addressing hard-to-treat tumors, will …See details»
Immunicum Set to Expand Research and Development Facilities in …
Feb 18, 2021 About Immunicum Immunicum is specialised in cell biology and develops novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. With complementary …See details»
Immunicum — Successful large share issue transforms outlook
Jun 27, 2019 Immunicum’s Q119 operating loss of SEK29.1m was in line with SEK28.8m in Q118. As expected, R&D costs comprised most of Immunicum’s expense accounting for …See details»
Immunicum continues cell therapy trials after positive kidney …
Sep 26, 2019 Sweden’s Immunicum has announced detailed results from its mid-stage trial of its oncology cell-based immunotherapy ilixadencel, which it says justify further clinical trials after …See details»